University of Thessaly (UTH)
Cardiovascular risk factors, thromboembolic outcomes and mortality of hospitalized COVID-19 patients in the 90-day post-discharge period
Abstract
dc:descriptionObjectives: Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. The risk and associated risk factors of post-discharge thromboembolism and death in hospitalized COVID-19 patients remain unclear. The aim of this study was to fill the current knowledge gap in post-discharge rates of VTE, ATE, all-cause mortality (ACM), and major complications in hospitalized patients with COVID-19. To this aim, we created a multicenter, prospective registry named CORE-19. Our second aim was to assess clinical and laboratory risk factors, as well as relevant medications, including anticoagulants, to predict risk of thromboembolic disease or death in the post-discharge period. Methods: Our prospective registry included consecutive patients with COVID-19 hospitalized within our multihospital system from 1 March to 31 May 2020. We captured demographics, comorbidities, laboratory parameters, medications, post-discharge thromboprophylaxis, and 90-day outcomes. Data from electronic health records, health informatics exchange, radiology database, and telephonic follow-up were merged. Primary outcome was a composite of adjudicated VTE, ATE, and all-cause mortality (ACM). Principal safety outcome was major bleeding (MB). Further, we investigated the post-discharge rates and associated risk factors of ATE, VTE, and ACM in a high-risk subpopulation of hospitalized COVID-19 patients with coronary artery disease (CAD),carotid artery stenosis (CAS), peripheral arterial disease (PAD), or ischemic stroke. Results: Among 4906 patients (53.7% male), mean age was 61.7 years. Comorbidities included hypertension (38.6%), diabetes (25.1%), obesity (18.9%), and cancer history (13.1%). Post-discharge thromboprophylaxis was prescribed in 13.2%. VTE rate was 1.55%; ATE, 1.71%; ΑCM, 4.83%; and major bleeding, 1.73%. Composite primary outcome rate was 7.13% and was significantly associated with advanced age (odds ratio [OR], 3.66; 95% confidence interval [CI]: 2.84-4.71), prior VTE (OR: 2.99; 95% CI: 2.00-4.47), intensive care unit (ICU) stay (OR: 2.22; 95% CI: 1.78-2.93), chronic kidney disease (CKD; OR: 2.10; 95% CI: 1.47-3.00), peripheral arterial disease (OR: 2.04; 95% CI: 1.10-3.80), carotid occlusive disease (OR: 2.02; 95% CI: 1.30-3.14), IMPROVE-DD VTE score ≥4 (OR: 1.51; 95% CI: 1.06-2.14), and coronary artery disease (OR: 1.50; 95% CI: 1.04-2.17). Post-discharge anticoagulation was significantly associated with reduction of the primary outcome (OR: 0.54; 95% CI: 0.47-0.81). In the high-risk subpopulation of 608 patients ATE rate was 27.3% (10.2% myocardial infarction, 10.1% ischemic stroke, 13.2% systemic embolism, 12.7% major adverse limb event); VTE rate was 6.9% (4.1% deep vein thrombosis, 3.6% pulmonary embolism); ACM rate was 9.5%; and the composite of ATE, VTE, or ACM 35.2% (214/608). Multivariate analysis showed significant association between this composite endpoint and age > 75 years (OR: 1.90, 95% CI: 1.22-2.94), PAD (OR: 3.23, 95% CI: 1.80-5.81), CAS (OR: 1.74, 95% CI: 1.11-2.75), congestive heart failure (CHF) (OR: 1.84, 95% CI: 1.02-3.35), previous VTE (OR: 3.08, 95% CI: 1.75-5.42), and ICU stay (OR: 2.93, 95% CI: 1.81-4.75).Conclusions: COVID-19 inpatients remain at high risk of VTE, ATE, and ACM through 90 days after discharge. Independent predictors of post-discharge major thromboembolic events and death include advanced age >75 years, cardiovascular risk factors (personal history of VTE, coronary artery disease, carotid occlusive disease, and peripheral arterial disease), CKD, IMPROVE-DD VTE score ≥4, and ICU stay. Discharge anticoagulants, mostly prophylactic doses, were associated with 46% decrease in the composite endpoint of major thromboembolism or ACM. High-risk COVID-19 inpatients with cardiovascular disease experience even higher rates of ATE, VTE, or ACM through 90 days post-discharge and associated independent risk factors include age > 75 years, PAD, CAS, CHF, previous VTE, and ICU admission. The identification of high-risk hospitalized COVID-19 patients, including those with established cardiovascular disease, may provide additional targets and prognostic indicators for the prevention of major thromboembolism and mortality after hospital discharge. Randomized controlled trials are needed to explore the role of antithrombotic agents, especially anticoagulant and add-on antiplatelet therapy, in the immediate post-discharge period.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Giannis, Dimitrios
- Γιαννής, Δημήτριος
Subjects
dc:subject × 21- Θρόμβωση
- COVID-19
- Κορονοϊός
- Καρδιαγγειακή θνητότητα
- Θρομβοεμβολικές επιπλοκές
- Καρδιαγγειακοί παράγοντες κινδύνου
- Θνητότητα
- Thrombosis
- Coronavirus
- Cardiovascular mortality
- Thromboembolic complications
- Cardiovascular risk factors
- Mortality
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ιατρική αυξημένης φροντίδας και Εντατική θεραπεία
- Επείγουσα ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Critical Care and Intensive Care Medicine
- Emergency Medicine
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57513